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Mouse hematopoiesis is initiated by long-term
hematopoietic stem cells (HSC) that differentiate
into a series of multipotent progenitors that
exhibit progressively diminished self-renewal
ability. In human hematopoiesis, populations
enriched for HSC activity have been identified,
as have downstream lineage-committed pro-
genitors, but multipotent progenitor activity
has not been uniquely isolated. Previous
reports indicate that human HSC are enriched
in LinCD34+CD38 cord blood and bone
marrow and express CD90. We demonstrate
that the LinCD34+CD38 fraction of cord
blood and bone marrow can be subdivided
into three subpopulations: CD90+CD45RA,
CD90CD45RA, and CD90CD45RA+. Utiliz-
ing in vivo transplantation studies and comple-
mentary in vitro assays, we demonstrate that
the LinCD34+CD38CD90+CD45RA cord
blood fraction contains HSC and isolate this
activity to as fewas10purifiedcells. Furthermore,
we report the first prospective isolation of a
population of candidate humanmultipotent pro-
genitors, LinCD34+CD38CD90CD45RA
cord blood.
INTRODUCTION
Hematopoiesis proceeds through an organized develop-
mental hierarchy initiated by hematopoietic stem cells
(HSC) that give rise to progressively more committed pro-
genitors and eventually terminally differentiated blood
cells (Bryder et al., 2006). Although the concept of the
HSC was not new, it was not until 1988 that it was shown
that this population could be prospectively isolated from
mouse bone marrow on the basis of cell-surface markers
using fluorescence-activated cell sorting (FACS) (Span-Cell Sgrude et al., 1988). Since that time, the surface immuno-
phenotype of the mouse HSC has become increasingly
refined, such that functional HSC can be isolated with
exquisite sensitivity, resulting in a purity of 1 in 1.3 cells
(Kiel et al., 2005). While our ability to prospectively isolate
mouse HSC has improved dramatically over the past
20 years, our understanding of the earliest events in the
human hematopoietic system lags far behind.
Both in vitro and in vivo experimental approaches have
been utilized to identify human HSC (Kondo et al., 2003).
The best in vitro assay of HSC activity is the long-term cul-
ture-initiating cell assay (LTC-IC), which requires culturing
of cells on bone marrow feeder cells to identify those
capable of producing hematopoietic cells for 6 weeks or
longer (Sutherland et al., 1989). Using this technique, can-
didate human HSC were identified by virtue of expression
of CD34 and CD90 (Thy1) and lack of lineage markers
(Lin) (Baum et al., 1992; Craig et al., 1993). Other studies
using the LTC-IC assay localized human HSC activity to
the LinCD34+CD38/lo fraction (Kondo et al., 2003).
Although these in vitro assays provide important informa-
tion regarding lineage potential and possibly self-renewal,
it is clear that definitive demonstration of HSC function
requires an in vivo assay.
Several in vivo models have been utilized to study hu-
man hematopoiesis. McCune and colleagues used the
SCID-hu mouse model to identify human HSC activity
amongLinCD34+CD90+cells (McCuneet al., 1988;Mur-
ray et al., 1995; Peault et al., 1993). Dick andcolleagues ini-
tially used SCID/beige/XID and, more recently, NOD/SCID
mice to assay normal human progenitor subpopulations
(Dick et al., 2001). By assessing long-term multipotent
human hematopoiesis in recipients and the ability to form
secondary and tertiary transplants, human HSC were
found to reside in the LinCD34+CD38/lo fraction of hu-
man progenitors (Bhatia et al., 1997; Cashman et al., 1997;
Hogan et al., 2002). Recently, the NOD/SCID/IL-2Rg null
strain (NOG) strain was shown to exhibit significantly
higher engraftment potential than other immunodeficient
mouse strains when transplanted with human hematopoi-
etic progenitors (Shultz et al., 2005). Transplantation of
20,000 LinCD34+CD38 human cord blood cells intotem Cell 1, 635–645, December 2007 ª2007 Elsevier Inc. 635
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age engraftment, with significant numbers of human cells
present in the peripheral blood (Ishikawa et al., 2005). Per-
haps the best in vivo demonstration of HSC function
comes from human trials of autologous mobilized periph-
eral blood in clinical transplantation, where long-term
engraftment was provided by transplantation of purified
CD34+CD90+ cells (Michallet et al., 2000; Negrin et al.,
2000; Vose et al., 2001). Together, these in vivo studies
support the idea that human HSC are contained in the
LinCD34+CD38CD90+ fraction of hematopoietic cells.
HSC are defined on the basis of two key properties: (1)
multipotency, defined as the ability to form all differenti-
ated blood cells, and (2) long-term self-renewal, defined
as the lifelong ability to give rise to progeny identical to
the parent through cell division. HSC are the only hemato-
poietic cells that possess these two properties; however,
there are hematopoietic cells that are multipotent, but
not capable of long-term self-renewal, termedmultipotent
progenitors (MPP). MPP lie immediately downstream of
HSC within the hematopoietic hierarchy and have been
identified in mouse bone marrow on the basis of their dis-
tinct surface immunophenotype (Christensen and Weiss-
man, 2001;Morrison et al., 1997;Morrison andWeissman,
1994). MPP have yet to be identified within the human
hematopoiesis hierarchy, but functional evidence sug-
gests that they exist. Retroviral or lentiviral marking of
LinCD34+CD38/lo cells prior to xenotransplantation
allowed investigators to track engrafted cells, resulting in
the observation that individual LinCD34+CD38/lo cells
had variable self-renewal and proliferation potential (Gue-
nechea et al., 2001; Mazurier et al., 2004; McKenzie et al.,
2006). Although it was not determined if the short-term
clones were multipotent, these observations suggest
that MPP are contained within the LinCD34+CD38/lo
fraction of human hematopoietic progenitors.
In this report,wedemonstrate that the LinCD34+CD38
fraction of human cord blood and bone marrow can be
divided into three subpopulations based on expression of
CD90 and CD45RA: CD90+CD45RA, CD90CD45RA,
and CD90CD45RA+. Using in vivo xenotransplantation
as well as complementary in vitro assays, we show that
the LinCD34+CD38CD90+CD45RA cord blood popu-
lation contains human HSC and isolate this activity to as
few as ten purified cells. In addition, we demonstrate that
this population resides at the top of the human hemato-
poietic developmental hierarchy. Finally, we report the first
identification and prospective isolation of a population of
candidate human multipotent progenitors, LinCD34+
CD38CD90CD45RA cord blood.
RESULTS
Identification of CD90/CD45RA Subpopulations
of LinCD34+CD38 Human Bone Marrow
and Cord Blood
Data from multiple investigators indicate that human HSC
activity resides in the CD90+ fraction of LinCD34+
CD38/lo cells. Using themarker CD45RA, three subpop-636 Cell Stem Cell 1, 635–645, December 2007 ª2007 Elsevieulations of LinCD34+CD38 bone marrow and cord
blood were identified: (1) CD90+CD45RA, (2) CD90
CD45RA, and (3) CD90CD45RA+ (Figure 1). In the
bone marrow, these populations comprised 30.3 ± 18.9%
(CD90+CD45RA), 37.7 ± 14.1% (CD90CD45RA),
and 24.7 ± 11.8% (CD90CD45RA+) of LinCD34+
CD38 cells (n = 10). In cord blood, these fractions consti-
tuted 25.2 ± 10.3% (CD90+CD45RA), 49.8 ± 11.4%
(CD90CD45RA), and 18.4 ± 8.4% (CD90CD45RA+)
of LinCD34+CD38 cells (n = 22). All three subpopula-
tions were isolated to >95% purity from cord blood and
bone marrow by FACS (see Figure S1 available online).
Methylcellulose Colony Formation and Replating
of CD90/CD45RA Subpopulations
In order to assess the lineage potential of the CD90/
CD45RA subpopulations, each was assayed for in vitro
colony formation in methylcellulose. Single cells of each
population were sorted into individual wells of a 96-well
plate containing complete methylcellulose. In all cases,
only a single colony was detected. CD90+CD45RA
cells formed all types of myeloid colonies, as did
CD90CD45RA cells (Figure 2A). No differences were
detected in plating efficiency or colony subtype distribu-
tion between these two subpopulations; however, the
CD90+CD45RA colonies were generally much larger
and faster growing. CD90CD45RA+ cells formed very
few colonies, suggesting that these cells possess limited
myeloid differentiation potential.
All colonies derived from individual cells were then
harvested, dissociated, and plated in complete methylcel-
lulose in order to determine replating efficiency, an in vitro
surrogate for self-renewal (Figure 2B). Seventy percent of
colonies derived from CD90+CD45RA cells were able
to form new colonies (in most cases, hundreds) upon
Figure 1. Identification of CD90/CD45RA Subpopulations of
LinCD34+CD38 Human Bone Marrow and Cord Blood
Normal human bone marrow (top) and cord blood (bottom) were
analyzed for expression of lineage markers, CD34, CD38, CD90, and
CD45RA by flow cytometry. The bone marrow sample was CD34-
enriched prior to analysis. The left panels are gated on lineage negative
(Lin) live cells, while the right panels are gated on LinCD34+CD38
cells. Data shown is representative of multiple samples of bone
marrow (n = 10) and cord blood (n = 22).r Inc.
Cell Stem Cell
Isolation of a Cord Blood Multipotent ProgenitorFigure 2. In Vitro Evaluation of the CD90/CD45RA Subpopulations of LinCD34+CD38 Cord Blood Reveals a Developmental
Hierarchy
(A) Methylcellulose colony formation: single cells from each CD90/CD45RA subpopulation were sorted into individual wells of a 96 well plate contain-
ing complete methylcellulose capable of supporting growth of all types of myeloid colonies. After 12–14 days, colonies were scored based on
morphology. The percent of each type of colony out of the total cells plated is indicated. Data presented is cumulative from three experiments of
60 cells each, for a total of 180 cells per subpopulation.
(B) Methylcellulose colony replating: all colonies derived from individual cells were harvested, dissociated, and replated in complete methylcellulose.
The formation of new colonies was scored based on morphology 12–14 days later. Upon replating, 42 out of 62 (70%) of CD90+CD45RA, 23 out of
70 (33%) of CD90CD45RA, and 0 out of 6 (0%) of CD90CD45RA+ colonies formed new colonies. The difference in replating efficiency between
CD90+CD45RA and CD90CD45RAwas statistically significant (p = 0.003). Data presented is the average of three independent experiments with
the indicated SEM.
(C) In vitro proliferation: 20 cells of each CD90/CD45RA subpopulation were clone sorted into individual wells of a 96-well plate containing serum-free
media supplemented with human LDL and cytokines. After 2 weeks in culture, cells were harvested and live cells counted by trypan blue exclusion.
The difference between the CD90+CD45RA and the CD90CD45RA subpopulations was statistically significant (p = 0.007). Data is representa-
tive of 3 independent experiments.
(D) In vitro hierarchical relationships among CD90/CD45RA subpopulations: CD90/CD45RA subpopulations were sorted in bulk into serum-free
media supplemented with human LDL and cytokines. Cells were cultured for 4 days and then reanalyzed by flow cytometry. All plots shown are gated
on LinCD34+CD38 cells; the left panels show the cell input and the right panels show the cells after 4 days in culture. Data shown is representative
of three independent experiments.replating. Thirty-three percent of colonies derived from
CD90CD45RA cells were able to form new colonies
(in most cases, fewer than 50). None of the colonies
derived from CD90+CD45RA cells were able to form
new colonies; however, very few colonies formed in the
first plating (n = 6). Thus, the CD90CD45RA sub-
population is able to form all myeloid cells, but has
reduced capacity for self-renewal compared to theCellCD90+CD45RA subpopulation, which is presumed to
contain HSC.
In Vitro Proliferation and Differentiation Identifies
a Hierarchy among the CD90/CD45RA
Subpopulations
The CD90/CD45RA subpopulations were also assayed for
in vitro proliferation in serum-free liquid culture. SingleStem Cell 1, 635–645, December 2007 ª2007 Elsevier Inc. 637
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of a 96-well plate containing serum-free media supple-
mented with Flt-3 ligand, SCF, TPO, IL-3, and IL-6 and
cultured for 2 weeks. At the end of the culture period,
live cells were counted. CD90+CD45RA cells prolifer-
ated extensively with a mean recovery of 345,000 cells;
CD90CD45RA cells proliferated to a lesser degree
with a mean recovery of 67,500 cells; and CD90
CD45RA+ cells proliferated poorly with few live cells
recovered (Figure 2C). These results support the observed
differences in methylcellulose colony size and suggest
that the CD90 subpopulations are less primitive than
the CD90+ subpopulation presumed to contain HSC.
In order to examine the potential hierarchical relation-
ships between the CD90/CD45RA subpopulations within
the LinCD34+CD38 fraction, each population was
sorted in bulk into serum-free media supplemented with
cytokines as described above. After 4 days in culture,
the cells were reanalyzed for expression of CD90 and
CD45RA (Figure 2D). While CD90+CD45RA cells gave
rise to all three subpopulations, CD90CD45RA cells
gave rise to both CD90 subpopulations, but not CD90+
cells. CD90CD45RA+ cells gave rise principally to itself
only. Together, these data establish an in vitro differentia-
tion hierarchy in which CD90+CD45RA cells give rise
to CD90CD45RA cells, which in turn give rise to
CD90CD45RA+ cells.
Long-Term In Vivo Multipotent Human
Hematopoiesis with Transplantation of as Few
as Ten LinCD34+CD38CD90+CD45RA Cord
Blood Cells
Newborn NOD/SCID/IL-2Rg null (NOG) mice were used in
xenotransplantation assays to determine the differentia-
tion potential and self-renewal ability of the CD90/
CD45RA subpopulations. Transplantation of 100 purified
CD90+CD45RA cells resulted in circulating human
CD45+ hematopoietic cells at 12 weeks, including both
CD13+ myeloid cells and CD19+ B cells, but not CD3+
T cells (Figure 3A). Several of these mice were followed
beyond 12 weeks (maximum 30 weeks), and all continued
to have detectable human myeloid cells at similar levels in
the peripheral blood (data not shown), indicating contin-
ued human engraftment. In order to isolate this activity
to as few cells as possible, ten purified CD90+CD45RA
cells were transplanted. At 12 weeks, few circulating hu-
man CD45+ cells were detected, and no CD13+ myeloid
cells were present (Figure 3A); however, analysis of the
bone marrow showed significant human engraftment
with both myeloid and lymphoid cells (Figure 3A). Suc-
cessful long-term human engraftment was observed in
3 out of 10 mice transplanted with ten CD90+CD45RA
cells, with the three successful engraftments coming
from independent cord blood samples.
Both CD13+ myeloid cells and CD19+ B cells were de-
tected in the blood and bone marrow of engrafted mice,
indicating that CD90+CD45RA cells possess lymphoid
and myeloid potential and are likely multipotent. Analysis
of the spleen from engrafted mice identified human638 Cell Stem Cell 1, 635–645, December 2007 ª2007 ElsevieCD45+CD3+ T cells (Figure S2), and staining of the bone
marrowwith glycophorin-A andCD61/41 identified human
erythroid cells and platelets (data not shown). To confirm
this flow cytometry-derived lineage analysis, human
CD45+ cells from both peripheral blood and bone marrow
were FACS-purified, and cytospin preparations were
stained with Wright-Giemsa. These stains confirmed the
presence of mature human lymphocytes, neutrophils,
and monocytes in the peripheral blood (Figure 3B, panels
1–3). In the bone marrow, both lymphocytes and maturing
myeloid cells were readily detected (Figure 3B, panel 4).
Figure 3. Long-Term In Vivo Multipotent Human Hematopoi-
esis with Transplantation of as Few as Ten LinCD34+CD38
CD90+CD45RA Cord Blood Cells
(A) In vivo engraftment of 100 or 10 CD90+CD45RA cells: 100 or 10
FACS-purified CD90+CD45RA- cells were transplanted into NOG
newborn mice as described. 12 weeks later peripheral blood and/or
bone marrow was harvested and analyzed by flow cytometry for the
presence of human CD45+ hematopoietic cells, myeloid cells
(hCD45+CD13+), and B lymphoid cells (hCD45+CD19+) cells. The
right plots are gated on human CD45+ cells.
(B) Wright-Giemsa stained cytospin preparations from CD90+
CD45RA engrafted mice: human CD45+ cells were purified by
FACS from peripheral blood (panels 1–3) or bone marrow (panel 4) of
mice engrafted with CD90+CD45RA cells. In the peripheral blood,
(1) lymphocytes, (2) neutrophils, and (3) monocytes were detected; in
the bone marrow (4) lymphocytes and maturing myeloid cells were
detected. (1003).r Inc.
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Cells Reconstitute the Peripheral Blood
of CD90/CD45RA Transplanted Mice
(A) Peripheral blood engraftment and lineage
analysis of CD90/CD45RA transplanted mice:
500 FACS-purified cells of each CD90/
CD45RA subpopulation, CD90+CD45RA
(top panels), CD90CD45RA (middle
panels), andCD90CD45RA+ (bottompanels),
were transplanted into NOG newborn mice as
described. Twelve weeks later, peripheral
blood was harvested and analyzed by flow
cytometry for the presence of human CD45+
hematopoietic cells, myeloid cells (hCD45+
CD13+), and B lymphoid cells (hCD45+CD19+)
cells. The right plots are gated on human
CD45+ cells.
(B) Summary of long-term (>12 weeks) peri-
pheral blood engraftment of CD90/CD45RA
subpopulations.
(C) Peripheral blood engraftment per 100
transplanted cells: the percent human
chimerism (left) and percent human myeloid
cells (right) per 100 transplanted cells is indi-
cated for each engrafted mouse. Each circle
or triangle represents an individual mouse
and the bar indicates the average. On average,
CD90+CD45RAmice developed 7-fold more
human chimerism than CD90CD45RA
mice, and this difference was statistically
significant (p = 0.02). The 7-fold difference in
percent human myeloid cells approached,
but did not achieve statistical significance
(p = 0.08).Collectively, these data indicate that LinCD34+CD38
CD90+CD45RA cord blood cells are capable of estab-
lishing long-term in vivo multipotent human hemato-
poiesis and that this activity can be isolated to as few as
ten cells.
Long-Term In Vivo Multipotent Human
Hematopoiesis Requires Transplantation
of More CD90CD45RA Cells Than
CD90+CD45RA Cells
All three CD90/CD45RA subpopulations of cord blood
were purified by FACS and transplanted into NOG
mice. Transplantation of both the CD90+CD45RA and
the CD90CD45RA subpopulations resulted in detect-
able human myeloid and B lymphoid cells in the periph-
eral blood 12 weeks after transplantation (Figure 4A). No
human cells were detected in the peripheral blood of
mice transplanted with the CD90CD45RA+ subpopula-
tion, even at time points as early as 4 weeks after trans-
plantation (Figure 4A). Multiple transplantation experi-
ments were conducted with independent cord blood
samples resulting in transplantation of between 100
and 4440 cells of each population (Figure 4B). The cumu-
lative data from these experiments showed that 12 of 13
mice (92%) transplanted with CD90+CD45RA cells andCell S15 of 17 mice (88%) transplanted with CD90CD45RA
cells contained human CD45+ cells in the peripheral
blood at least 12 weeks after transplantation (Figure 4B).
In the engrafted mice, the average human CD45+ chime-
rism was 3.7% for the CD90+CD45RA transplants
compared to 4.0% for the CD90CD45RA transplants;
the percentage of myeloid cells among human CD45+
cells was 6.7% for the CD90+CD45RA transplants
compared to 7.1% for the CD90CD45RA transplants
(Figure 4B). Because different cell numbers were used in
each of these transplantation experiments, the engraft-
ment per 100 transplanted cells was determined. The
CD90+CD45RA engrafted mice averaged 7-fold
greater human chimerism and 7-fold greater human
myeloid cells than the CD90CD45RA engrafted mice
(Figure 4C). The difference in human chimerism was sta-
tistically significant with p = 0.02, while the difference in
human myeloid cells approached statistical significance
with p = 0.08.
Analysis of the bone marrow of transplanted mice
revealed human myeloid and B cells 12 weeks after trans-
plantation of CD90+CD45RA and CD90CD45RA
cells (Figure 5A). No human cells were detected in the
bone marrow of mice transplanted with the CD90
CD45RA+ population (data not shown). Cumulative datatem Cell 1, 635–645, December 2007 ª2007 Elsevier Inc. 639
Cell Stem Cell
Isolation of a Cord Blood Multipotent ProgenitorFigure 5. Human Lymphoid and Myeloid
Cells Reconstitute the Bone Marrow of
CD90+CD45RA Transplanted Mice
More Efficiently Than CD90CD45RA
Transplanted Mice
(A) Bonemarrow engraftment and lineage anal-
ysis of CD90/CD45RA transplanted mice:
500 FACS-purified CD90+CD45RA cells
(top panels) and CD90CD45RA cells (bot-
tom panels) were transplanted into NOG new-
born mice as described. 12 weeks later bone
marrow was analyzed by flow cytometry for
the presence of human CD45+ hematopoietic
cells, myeloid cells (hCD45+CD33+), and B
lymphoid cells (hCD45+CD19+) cells. The right
plots are gated on human CD45+ cells.
(B) Summary of long-term (>12 weeks) bone
marrow engraftment of CD90/CD45RA sub-
populations.
(C) Bone marrow engraftment per 100
transplanted cells: the percent human chime-
rism (left) and percent human myeloid cells
(right) per 100 transplanted cells is indicated
for each engrafted mouse. Each circle or
triangle represents an individual mouse and
the bar indicates the average. On average,
CD90+CD45RA mice developed 9-fold
more humanchimerism thanCD90CD45RA
mice, and this difference was statistically
significant (p = 0.001). The 9-fold difference
in percent human myeloid cells approached,
but did not achieve statistical significance
(p = 0.07).
(D) Summary of long-term (>11 weeks) bone
marrow engraftment of limiting numbers (<100
cells) of CD90/CD45RA subpopulations: 50 or
70 double FACS-purified CD90+CD45RA or
CD90CD45RA cellswere transplanted intoNOGnewbornmice asdescribed. At least 11weeks later, bonemarrowwas analyzed by flowcytometry
for the presence of human CD45+ hematopoietic cells, myeloid cells (hCD45+CD33+), B cells (hCD45+CD19+) cells, and T cells (hCD45+CD3+). In
1 out of 5 mice transplanted with CD90CD45RA cells, a small population of T cells (0.2%) was detected in the bone marrow in the absence of
myeloid and B cells. The difference in successful engraftment was statistically significant (p = 0.008).showed that 8 of 8 mice (100%) transplanted with
CD90+CD45RA cells and 8 of 9mice (89%) transplanted
with CD90CD45RA cells contained human CD45+
cells in the bone marrow at least 12 weeks after transplan-
tation (Figure 5B). In the engrafted mice, the average
human chimerism was 19.9% for the CD90+CD45RA
transplants compared to 4.4% for the CD90CD45RA
transplants; the percent myeloid of total human CD45+
cells was 24.3% for the CD90+CD45RA transplants
compared to 26.6% for the CD90CD45RA transplants
(Figure 5B). In order to normalize for cell number, bone
marrow engraftment per 100 transplanted cells was deter-
mined. The CD90+CD45RA engrafted mice averaged
9-fold greater human chimerism and 9-fold greater human
myeloid cells than the CD90CD45RA engrafted mice
(Figure 5C). The difference in human chimerism was sta-
tistically significant with p = 0.001, while the difference in
human myeloid cells approached statistical significance
with p = 0.07.
Analysis of the spleens of CD90+CD45RA and
CD90CD45RA transplanted mice identified human
CD45+ cells consisting of rare myeloid cells, numerous640 Cell Stem Cell 1, 635–645, December 2007 ª2007 ElsevierB cells, and occasional T cells. No human cells were de-
tected in the spleens of mice transplanted with
CD90CD45RA+ cells. Significant numbers of T cells
were detected in only a subset of mice transplanted with
either engrafting population (Figure S2). Determining
splenic engraftment per 100 transplanted cells revealed
that CD90+CD45RA engrafted mice averaged 7-fold
greater human chimerism than the CD90CD45RA en-
grafted mice, and this difference was statistically signifi-
cant. However, no statistically significant difference was
detected in the T cell percentage (Figure S2B). Finally,
bone marrow from mice engrafted with CD90CD45RA
cells was found to contain GPA-positive human erythroid
cells and CD61/CD41-positive human platelets (data not
shown), indicating that these cells are multipotent.
To investigate the minimum number of cells required for
successful engraftment, 50 or 70 CD90CD45RA or
CD90+CD45RA cells were double FACS-purified from
2 independent cord blood samples and transplanted into
NOG mice. At least 11 weeks later, bone marrow was
analyzed for human engraftment. All mice (n = 4) trans-
planted with CD90+CD45RA cells contained humanInc.
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CD34+ Cells Identifies a Hierarchy
among the CD90/CD45RA Subpopula-
tions
(A) Summary of long-term (>12 weeks) human
CD34+ bone marrow engraftment of CD90/
CD45RA subpopulations.
(B) Bone marrow human CD34+ engraftment
per 100 transplanted cells: the percentage of
human CD34+ cells in total bone marrow per
100 transplanted cells is indicated for each en-
grafted mouse. Each circle represents an indi-
vidual mouse and the bar indicates the
average. On average, CD90+CD45RA mice
contained 8-fold more human CD34+ cells
than CD90CD45RA mice, and this differ-
ence was statistically significant (p = 0.01).
(C) Analysis of CD90/CD45RA expression on
LinCD34+CD38 bone marrow cells in
CD90/CD45RA transplanted mice: 500 FACS-
purified CD90+CD45RA cells (top panels)
and CD90CD45RA cells (bottom panels)
were transplanted into NOG newborn mice as
described. Twelve weeks later, bone marrow
was analyzed by flow cytometry for the expres-
sion of lineage markers, CD34, CD38, CD90,
and CD45RA. The left plots are gated on
LinCD34+ cells, and the right plots are gated
on LinCD34+CD38 cells.
(D) CD90/CD45RA subpopulations within engrafted bone marrow: the percentage of CD90+CD45RA (left), CD90CD45RA (middle), and
CD90CD45RA+ (right) cells out of LinCD34+CD38 bone marrow cells from mice engrafted with CD90+CD45RA and CD90CD45RA cells
is indicated. Each circle, triangle, or square represents an individual mouse. Only mice with greater than 10 LinCD34+CD38 cells were included
(n = 7 transplanted with CD90+CD45RA cells, and n = 4 transplanted with CD90CD45RA cells).myeloid andB cells, while nomice (n = 5) transplantedwith
CD90CD45RA cells did (Figure 5D). This difference
was statistically significant with p = 0.008. One of the
CD90CD45RA transplanted mice did contain a small
population (0.2%) of human T cells, indicating that it
must have engrafted at an early time point. To directly in-
vestigate early engraftment, 50 double FACS-purified
cells were transplanted into NOG newborn mice. Four
weeks later, bone marrow of all transplanted mice, both
CD90+CD45RA (n = 2) and CD90CD45RA (n = 2),
contained human myeloid and B cells.
In summary, both the CD90+CD45RA and CD90
CD45RA subpopulations are capable of establishing
long-term in vivo multipotent human hematopoiesis, with
similar percentages of myeloid and lymphoid cell produc-
tion. However, the CD90CD45RA cells have a lower
engraftment capacity as they require transplantation of
more cells for long-term engraftment and generate fewer
human cells per cell-equivalent transplant.
In Vivo Analysis of Human CD34+ Cells Identifies
a Hierarchy among the CD90/CD45RA
Subpopulations
In order to assess the hierarchical relationships among the
CD90/CD45RA subpopulations in vivo, human CD34+
progenitor cells from the bone marrows of engrafted
mice were analyzed 12 weeks after transplantation. In
mice transplanted with CD90+CD45RA cells, the bone
marrow contained, on average, 6.4% human CD34+ cellsCell Scompared to 1.3% human CD34+ cells in mice trans-
planted with CD90CD45RA cells (Figure 6A). CD34+
engraftment per 100 transplanted cells averaged 8-fold
greater in CD90+CD45RA engrafted mice than
CD90CD45RA engrafted mice, and this difference
was statistically significant (Figure 6B). This 8-fold sta-
tistically significant difference was also present when
comparing the percentage of LinCD34+ cells in total
bone marrow (data not shown). Within the engrafted
LinCD34+ fraction, there were no differences between
CD90+CD45RA and CD90CD45RA engrafted mice
with respect to the percentages of CD34+CD38+ or
CD34+CD38 cells (Figure 6A). Thus, CD90CD45RA
cells appear to be able to generate progenitor cells in
similar proportions to CD90+CD45RA cells, but are
less efficient in doing so in vivo.
Human LinCD34+CD38 cells in the bone marrow of
engrafted mice were also analyzed for the expression
of CD90 and CD45RA. All three CD90/CD45RA subpopu-
lations were detected in the bone marrow of mice trans-
planted with CD90+CD45RA cells; however, only the
two CD90 subpopulations were detected in mice trans-
planted with CD90CD45RA cells (Figures 6C and 6D).
In some mice transplanted with CD90CD45RA cells,
only CD90CD45RA+ cells were detected. Together,
these data establish an in vivo differentiation hierarchy
among LinCD34+CD38 cord blood cells proceeding
from CD90+CD45RA to CD90CD45RA to CD90
CD45RA+ cells.tem Cell 1, 635–645, December 2007 ª2007 Elsevier Inc. 641
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in the CD90+CD45RA Subpopulation
Self-renewal is the key property distinguishing HSC from
MPP and is defined by the ability to sustain long-term
hematopoiesis and generate successful secondary
transplants. Since both the CD90+CD45RA and
CD90CD45RA subpopulations demonstrated the abil-
ity to establish long-term in vivo multipotent hematopoie-
sis, we next assessed their ability to generate successful
secondary transplants. Human CD34+ cells were purified
from whole bone marrow of primary engrafted mice, and
equal numbers of CD34+ cells were transplanted into
NOG newbornmice. Bonemarrows from these secondary
recipients were analyzed at least 10 weeks after trans-
plantation. In one experiment, 130,000 human CD34+
cells were transplanted into secondary recipients. Human
CD45+ cells and human myeloid cells were detected in
8 of 8 mice (100%) from CD90+ primary transplants, but
only 2 of 5 mice (40%) from CD90 primary transplants
(Figures 7A and 7B). In a second experiment, 70,000
human CD34+ cells were transplanted into secondary
recipients. Human CD45+ cells and human myeloid cells
were detected in 4 of 4 mice (100%) from CD90+ primary
transplants, but only 1 of 3 mice (40%) from CD90
primary transplants (Figures 7A and 7C). This difference,
12 of 12 (100%) for CD90+ versus 3 of 8 (37.5%) for
CD90, was statistically significant with p = 0.004. These
data indicate that the CD90+CD45RA subpopulation
is enriched for the ability to generate successful second-
ary transplants compared to the CD90CD45RA
subpopulation.
DISCUSSION
HSC are defined by two key functional properties: (1) mul-
tipotency, defined as the ability to form all differentiated
blood cells, and (2) long-term self-renewal, defined as
the ability to give rise to progeny identical to the parent
through cell division. It is this property of self-renewal
that distinguishes HSC from multipotent progenitors and
is experimentally demonstrated through the ability to gen-
erate successful secondary transplants. We show here
that both CD90+CD45RA and CD90CD45RA cord
blood cells are able to establish long-term multipotent
hematopoiesis in vivo, and that the CD90+CD45RA sub-
population is enriched for the ability to generate success-
ful secondary transplants. We conclude that the
CD90+CD45RA subpopulation contains HSC, while the
CD90CD45RA subpopulation contains candidate mul-
tipotent progenitors. This represents the first identification
and prospective isolation of a population of candidate
human multipotent progenitors.
Both the CD90+CD45RA and CD90CD45RA cells
are able to establish multipotent long-term human hema-
topoiesis in vivo; however, the CD90CD45RA subpop-
ulation requires more cells to accomplish this as indicated
by the failure of 50 and 70 cell transplants to long-term
engraft, unlike the CD90+CD45RA subpopulation, which
engrafts long-termwith as few as ten cells. There are three642 Cell Stem Cell 1, 635–645, December 2007 ª2007 Elsevierpossibilities to explain these results. First, it is possible
that the CD90CD45RA cells are contaminated with in-
frequent CD90+CD45RA cells, as CD90 expression is
present on a continuum and not separable into discrete
subpopulations. The second alternative is that the
CD90CD45RA cells do contain HSC, but at a lower fre-
quency than the CD90+CD45RA cells. Third, the
CD90CD45RA cells may have reduced capacity to
home to the bone marrow, which could account for the
in vivo functional differences observed, although this
would not account for the differences in methylcellulose
colony replating. Ultimately, our data do not discriminate
among these three possibilities. Nevertheless, the fact
that 50 CD90CD45RA cells show myeloid and B lym-
phoid engraftment at 4 weeks, but not 12 weeks, indicates
that this fraction contains non-HSC multipotent
cells. Thus, we have demonstrated that CD90CD45RA
cells are multipotent, exhibit a reduced and incom-
plete capacity for self-renewal, and lie downstream of
Figure 7. Enrichment of Secondary Transplant Ability in the
CD90+CD45RA Subpopulation
(A) Summary of long-term (>10 weeks) bone marrow engraftment in
secondary transplants from mice engrafted with either CD90+ or
CD90 subpopulations. The difference in successful secondary
engraftment, 12 of 12 (100%) for CD90+ versus 3 of 8 (37.5%) for
CD90, was statistically significant with p = 0.004.
(B) Bonemarrow engraftment in secondary recipients from experiment
1: primarymice were transplantedwith 2000 cells of the indicated pop-
ulation. The percent human chimerism (left) and percent myeloid cells
of total human CD45+ cells (right) is indicated for each secondary
mouse. Each circle or triangle represents an individual mouse.
(C) Bonemarrow engraftment in secondary recipients from experiment
2: primary mice were transplanted with 500 cells of the indicated pop-
ulation. The percent human chimerism (left) and percent myeloid cells
of total human CD45+ cells (right) is indicated for each secondary
mouse. Each circle or triangle represents an individual mouse.Inc.
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Isolation of a Cord Blood Multipotent ProgenitorCD90+CD45RA cells in the hematopoietic hierarchy. We
conclude that CD90CD45RA cells are a candidate
multipotent progenitor.
Hematopoiesis proceeds through an organized hierar-
chy in which lineage potential becomes increasingly
restricted and a given population can only give rise to
downstream populations.We investigated the hierarchical
relationships between the CD90/CD45RA subpopulations
of LinCD34+CD38 cord blood and found that both
in vitro and in vivo, the CD90+CD45RA population gives
rise to itself and both the CD90CD45RAand
CD90CD45RA+ subpopulations. CD90CD45RA
cells do not give rise to CD90+ cells, but can form both
CD90 subpopulations. In vitro, the CD90CD45RA+
cells give rise principally to itself only. These results estab-
lish a hierarchy among LinCD34+CD38 cord blood
cells in which CD90+CD45RA cells are upstream of
CD90CD45RA cells, which are upstream of CD90
CD45RA+ cells (Figure S4). Several investigators have
reported long-term engraftment with LinCD34+CD38/
lo cord blood cells. As CD38 exhibits a continuum of
expression on LinCD34+ cells, it is possible that some
CD38lo cells were included in our purified subpopulations.
Additional xenotransplantation experiments will be neces-
sary to determine the function and hierarchical relation-
ship of LinCD34+CD38lo cord blood cells to our defined
subpopulations.
CD90 and CD45RA identify a third population within the
LinCD34+CD38 fraction of cord blood and bone mar-
row, the CD90CD45RA+ subpopulation. The experi-
ments outlined here to identify the differentiation and
self-renewal potential of this population were unsuccess-
ful. Transplantation with up to 900 of these cells does not
result in any circulating human hematopoietic cells at
4 weeks after transplantation, and there are no detectable
human cells in the bone marrow at 12 weeks. It is possible
that in vivo functional engraftment of this population will
require transplantation of manymore cells than performed
here, whichwas limited by the lower frequency of this pop-
ulation in cord blood. Furthermore, these cells have
extremely poor methylcellulose colony forming ability,
yielding only 6 colonies from 180 plated cells, suggesting
that they possess limited myeloid differentiation potential.
These cells also did not proliferate in liquid culture under
conditions able to promote the growth of the other two
subpopulations. It is interesting to note that cells with
this immunophenotype can be found within the bone mar-
row of mice engrafted with either the CD90+CD45RA
or CD90CD45RA subpopulation. Thus, it is likely that
they contribute to ongoing human hematopoiesis, but at
this time cannot be placed within the hematopoietic hier-
archy (Figure S4).
Numerous xenotransplantation experiments have re-
ported the successful enrichment of human HSC activity
in LinCD34+CD38–/lo fractions of human hematopoietic
progenitors through the demonstration of long-termmulti-
potent engraftment and successful secondary transplan-
tation (Dick et al., 2001; McKenzie et al., 2006). In pub-
lished reports, successful secondary engraftment hasCell Srequired primary transplantation of large numbers of cells,
minimally thousands and usually many more. We report
here long-term in vivo human engraftment and successful
secondary engraftment with transplantation of 500 puri-
fied LinCD34+CD38CD90+CD45RA cord blood
cells. The major differences between our results and
previous reports are (1) the use of the NOG newborn
mice, which appear to be well-suited for human hemato-
poietic engraftment and (2) the combination of
LinCD34+CD38CD90+CD45RA markers for HSC
purification. With this immunophenotype and xenotrans-
plantation assay, we have directly isolated cord blood
HSC activity to fewer cells than in previous reports.
Implications for Human Acute Myeloid Leukemia
Analogous to normal hematopoiesis, human acute mye-
loid leukemia (AML) is organized as a hierarchy initiated
by leukemia stem cells (LSC) that are able to self-renew
and give rise to all the cells within the leukemia (Tan
et al., 2006; Wang and Dick, 2005). In a series of xeno-
transplantation experiments, Dick and colleagues first
demonstrated the existence of human AML LSC and
localized them to the LinCD34+CD38 fraction of AML
(Bonnet and Dick, 1997; Lapidot et al., 1994). Based on
these observations, they have proposed a model in which
HSC are the cell of origin for AML LSC (Wang and Dick,
2005). However, subsequent experiments indicated that
AML LSC, unlike HSC, do not express CD90 (Blair et al.,
1997; Miyamoto et al., 2000). There are two hypotheses
to account for this difference: (1) AML LSC are indeed
derived from HSC but have aberrantly lost expression of
CD90, or (2) AML LSC do not derive from HSC but instead
come from a downstream progenitor that lacks expres-
sion of CD90.
Evidence supporting the second hypothesis comes
from our previous studies of AML1-ETO translocation-
associated AML in atom bomb survivors from Hiroshima
(Miyamoto et al., 2000). Similar to other investigators,
we found that the AML LSC were contained in the
LinCD34+CD38CD90 fraction (Blair et al., 1997;
Miyamoto et al., 2000). However, when the bone marrows
of long-term disease-free survivors were examined, the
AML1-ETO translocation was detected in LinCD34+
CD38CD90+ nonleukemic HSC. This demonstrates
that preleukemic genetic changes can take place within
HSC, but ultimate transformation to AML LSC requires
additional mutations that do not occur in HSC but instead
take place in a CD90 downstream population. We now
present evidence identifying this CD90 downstream
population as MPP.
Why does this matter? If the normal counterpart to long-
term self-renewing AML LSC is not capable of long-term
self-renewal itself, then AML LSC must have undergone
mutational or epigenetic activation of a self-renewal path-
way. These changes, when identified, become potential
targets for therapeutic intervention to eradicate the LSC.
Evidence for aberrant activation of self-renewal in LSC
comes from our previous studies of human blast crisis
CML, where normally non-self-renewing cells transformtem Cell 1, 635–645, December 2007 ª2007 Elsevier Inc. 643
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pathway (Jamieson et al., 2004). Through comparisons
between AML LSC and the newly identified MPP, we
hope to identify genetic and/or epigenetic events that
lead to the transformation of MPP into AML LSC.
EXPERIMENTAL PROCEDURES
Human Samples
Normal human bone marrow mononuclear cells were purchased from
AllCells Inc. (Emeryville, CA). Human cord blood was collected from
placentas and/or umbilical cords obtained from the Stanford Medical
Center, according to an IRB-approved protocol (Stanford IRB#
5637). Mononuclear cells were prepared using Ficoll-Paque Plus (GE
Healthcare, Fairfield, CT), and cryopreserved in 90% FBS/10%
DMSO. All experiments were conducted with cryopreserved cord
blood cells that were thawed and washed with IMDM containing
10% FBS. In some cases, CD34+ cells were enriched using MACS
(Miltenyi Biotec, Germany) or Robosep (Stem Cell Technologies,
Canada) immunomagnetic beads.
Flow Cytometry Analysis and Cell Sorting
A panel of antibodies was used for analysis and sorting of progenitor
subpopulations, as well as lineage analysis of human chimerism/
engraftment, and used to stain cell suspensions (Supplemental
Experimental Procedures). Cells were either analyzed or sorted using
a FACSAria cytometer (BD Biosciences). Analysis of flow cytometry
data was performed using FlowJo Software (Treestar, Ashland, OR).
Raw engraftment data is provided in Figure S3. Statistical analysis us-
ing Student’s t test or Fisher’s exact test was performed withMicrosoft
Excel and/or GraphPad Prism (San Diego, CA) software.
In Vitro Assays: Cytology, Methylcellulose,
and Liquid Culture
For cytologic analysis, sorted cells were centrifuged onto slides using
a Shandon Cytocentrifuge 4 (Thermo Scientific, Waltham, MA), and
stained with Wright-Giemsa. Photomicrographs were taken using a
1003 objective under oil.
Methylcellulose colony formation was assayed by clone-sorting sin-
gle cells into individual wells of a 96-well plate, each containing 100 ml
of complete methylcellulose (Methocult GF+ H4435, Stem Cell Tech-
nologies). Plates were incubated for 12–14 days at 37C then scored
based on morphology. All colonies were harvested, dissociated by
resuspending in sterile PBS, and replated into individual wells of
a 24-well plate, each containing 500 ml of complete methylcellulose.
Plates were incubated for 1214 days at 37C, after which replating
was determined by assessing colony formation. Statistical analysis
using Student’s t test was performed with Microsoft Excel and/or
GraphPad Prism (San Diego, CA) software.
In vitro proliferationwas assayed by clone-sorting single cells into in-
dividual wells of a 96-well plate, each containing 100 ml of StemSpan
media (Stem Cell Technologies), supplemented with 40 mg/ml human
LDL (Sigma-Aldrich) and cytokines (R&D Systems, Minneapolis, MN):
100 ng/ml Flt-3 ligand, 100 ng/ml SCF, 50 ng/ml TPO, 20 ng/ml IL-3,
and 20 ng/ml IL-6. Plates were incubated for 14 days at 37C, after
which live cells were counted by trypan blue exclusion. For in vitro
differentiation assays, cells were sorted in bulk into this same culture
media and incubated for 3 to 4 days at 37C, after which cells were
harvested and analyzed by flow cytometry. Statistical analysis using
Student’s t test was performed with Microsoft Excel and/or GraphPad
Prism (San Diego, CA) software.
Mouse Transplantation
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice (NOG) were obtained from The
Jackson Laboratory (Bar Harbor, ME) and bred in a Specific Patho-
gen-Free environment per Stanford Administrative Panel on Labora-
tory Animal Care guidelines (Protocol 10725). P0-P2 newborn pups644 Cell Stem Cell 1, 635–645, December 2007 ª2007 Elsevierwere conditioned with 100 rads of gamma irradiation up to 24 hr prior
to transplantation (Ishikawa et al., 2005). Desired cells were resus-
pended in 20–40 ml of PBS containing 2% FBS and transplanted intra-
venously via the anterior facial vein using a 30- or 31-gauge needle. For
secondary transplants, human CD34+ bonemarrow cells from primary
engrafted mice were enriched using MACS immunomagnetic beads
(Miltenyi Biotec), and transplanted into newborn NOG recipients.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures and four figures and can be found with this article online at
http://www.cellstemcell.com/cgi/content/full/1/6/635/DC1/.
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